Predictors of end stage lung disease in systemic sclerosis

V Steen

Recognition of the two types of lung disease is important because their predictors and treatment differ

Pulmonary disease is now the leading cause of death in patients with scleroderma. Of the 2000 patients in the Pittsburgh scleroderma databank, 211 patients have died of lung disease over the past 20 years. One hundred and thirteen died from isolated pulmonary hypertension and 98 died of pulmonary interstitial fibrosis. These account for 21.5% of the 981 deaths and 44% of the scleroderma related deaths. Recently, progress has been made in the treatment of specific lung problems in scleroderma so it is imperative that we have a better understanding of the predictors of these complications. Most important is the acknowledgement and recognition that there are two types of lung disease in scleroderma which are very different in their pathogenesis, clinical associations, predictive factors, and treatment. The investigators of “Predictors of end stage lung disease in a cohort of patients with scleroderma” in this issue of the Annals admit that a limitation of their study was that they were unable to separate their patients into the two types of lung disease. By combining these two types of lung disease they were unable to identify factors that would likely be predictors of one of the forms of lung disease. It is extremely important to look carefully at the two types of lung disease individually and not lump them all together as end stage lung disease.

PULMONARY INTERSTITIAL FIBROSIS

Pulmonary interstitial fibrosis is felt to result from an alveolitis, which leads to interstitial fibrosis. In some patients there may be a significant vascular component, as there is in other manifestations of the disease. However, the interactions of these two components is incompletely understood and thus, we will focus primarily on the inflammation and fibrosis component. In interstitial lung disease, treatment with cyclophosphamide may be helpful for the inflammatory aspects of the disease, which occur before the development of severe fibrosis, though this is still experimental. High resolution computed tomography and bronchoalveolar lavage are the primary tools used to determine the extent of continuing inflammation in patients with scleroderma, but before performing these tests we must identify patients who are at high risk of having inflammation.

**Forced vital capacity**

A study of patients with severe interstitial fibrosis showed that although symptoms of lung disease did not develop early in the course, the loss of volume on pulmonary function testing was greatest in the first four years of disease. This is consistent with Morgan’s study, which confirmed that the presence of an abnormal forced vital capacity (FVC) early in the disease is one of the most important risk factors for end stage lung disease. In another study, we found that 62% of the patients who ever reached an FVC of <55% of the predicted value did so in the first five years after the onset of their very first symptom related to scleroderma.

“An early abnormal FVC is an important risk factor for end stage interstitial lung disease”

Patients with more than five years of disease who previously have had normal or only mildly abnormal FVCs are much less likely to develop severe fibrotic disease later in the course of their disease. They may have significant restrictive disease that developed early in their illness, but several studies have shown that unlike idiopathic pulmonary fibrosis, progression of disease in scleroderma does not always occur. Many patients have mild to moderate disease which stabilises. These patients may have a further slow decline in FVC but it appears that early disease is the time at which patients are at greatest risk for inflammation and subsequent progressive interstitial fibrotic disease. Thus, in the first five years of disease patients should have pulmonary function tests (PFTs) monitored closely, every six months, until lung function stabilises. Patients with very early disease who already have a decreased FVC and the patient with a documented decreasing FVC are those who should be identified for further study even if they are asymptomatic. In our series of patients with severe lung disease, although patients died after 10 years of disease, most of these patients did not develop any pulmonary symptoms until after they had significantly decreased FVCs.

**Diffusing capacity**

The diffusing capacity usually parallels the decrease in the vital capacity and it is not the initial or the most sensitive test to use to identify patients at increased risk for fibrosis. The vascular component in scleroderma interferes with the diffusing capacity, preventing it from being a good marker in isolation from the vital capacity. We will see later that it is the diffusing capacity that is the most important measure in identifying patients at risk for the vasculopathy causing pulmonary hypertension.

**Antitopoisomerase antibody**

Antitopoisomerase antibody has consistently been associated with interstitial fibrosis, although it does not predict severe fibrosis. Some patients with the antibody have only mild fibrosis and other patients without the antibody have severe fibrosis. However, the antibody does identify patients at increased risk for some fibrosis. Anticentromere antibody has consistently been negatively associated with severe interstitial fibrosis. These patients almost never have severe fibrosis. However, patients with limited scleroderma with antitopoisomerase are at increased risk of severe fibrosis. In interstitial lung disease it appears that the antibody markers are stronger predictors than the scleroderma subsets of limited and diffuse scleroderma. Several studies have not shown a strong association between the severity of fibrosis and the extent and severity of skin thickening.

This is partly because there are patients with limited scleroderma (often with antitopoisomerase antibody) with fibrosis but also patients with diffuse scleroderma and anti-RNA polymerase III who have the most severe skin thickening, but they have a decreased incidence of severe lung disease. The nuclear autoantibodies, anti-U3 RNP antibody and anti TH/To, are also associated with an increased risk of pulmonary disease. The strong association of anti-U3 RNP and antitopoisomerase with the African-American race clearly makes these patients with scleroderma at significantly increased risk for severe interstitial fibrosis. The associations of these antibodies with specific types of lung abnormalities are strong evidence that they reflect something in the pathogenesis of the overall disease that differentiates patients into one or another type of disease pattern.

**Other factors**

Other features such as sedimentation rate and proteinuria (as found in this
Carbon monoxide transfer factor

The carbon monoxide transfer factor ($T_{LCO}$) is the best clue for predicting the development of isolated pulmonary hypertension. The vast majority of patients with scleroderma have a markedly decreased $T_{LCO}$ at the time of diagnosis of pulmonary hypertension.¹⁹

“$T_{LCO}$ is the best predictor of pulmonary hypertension”

Our recently completed case-control study of risk factors in 106 patients with pulmonary hypertension showed that the $T_{LCO}$ was a mean of 52% of the predicted value five years before the diagnosis of pulmonary hypertension (compared with 80% in patients without pulmonary hypertension).²² In a small subset of patients who had serial PFTs for 15 years before the diagnosis of pulmonary hypertension, there was a linear decrease of the $T_{LCO}$ from 80% of the predicted value at the time of the first PFT down to 40% of the predicted value at the time of diagnosis of pulmonary hypertension. Most of these patients had minimal to no interstitial disease and thus their FVCs were >70% of the predicted normal value. In patients who have some fibrosis with a mildly decreased FVC, an FVC/$T_{LCO}$ ratio of 1.6–1.8 helps to identify an increased likelihood of having pulmonary hypertension.²³

Echocardiograms

Echocardiograms can be used to screen for pulmonary hypertension, although pulmonary artery pressures are often unreliable or cannot be determined for technical reasons.²⁴ Also, a significant number of patients have a false positive or low level increase in pulmonary pressures. A right heart catheterisation is necessary to confirm the presence and degree of pulmonary hypertension. Additional studies are necessary to determine the significance and natural history of this “mild” type of pulmonary hypertension and, more importantly, whether early intervention with these newer agents can prevent or alleviate the development of the deadly form of pulmonary hypertension.

Anticentromere antibody

The anticentromere antibody is highly associated with limited scleroderma and it confirmed the impressions of an increased incidence of isolated pulmonary hypertension in limited scleroderma. However, patients with limited scleroderma without anticentromere antibody have similar risks of getting this type of pulmonary hypertension.²⁷ Patients with typical diffuse scleroderma and/or antiproteinase are much less likely to get isolated pulmonary hypertension, although they do develop pulmonary hypertension secondary to severe interstitial fibrosis. There is a subset of patients, many of whom have a nucleolar antinuclear antibody pattern, either U3-RNP or anti-Th antibody, who develop a moderate amount of interstitial fibrosis early in their disease and then later get severe pulmonary hypertension which is out of proportion to the degree of severity of the fibrosis. The ratio of the FVC to $T_{LCO}$ as described above can be helpful in differentiating the type of lung disease of these patients.

In summary, African-American patients with less than five years of diffuse scleroderma with a topoisomerase antibody and a decreased FVC are at the greatest risk for developing severe pulmonary fibrosis. In contrast patients with more than 10 years of limited scleroderma and an anticentromere antibody and a marked decrease in the $T_{LCO}$ are at greatest risk for getting isolated pulmonary hypertension.

### Table 1 Algorithm for lung disease in systemic sclerosis

<table>
<thead>
<tr>
<th>Clinical findings</th>
<th>Type of lung disease</th>
<th>Severe end stage</th>
<th>PF +/- alveolitis, excessive PHT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vascopathy, isolated PHT</td>
<td>Diffuse &gt; limited</td>
<td>Diffuse &gt; limited</td>
</tr>
<tr>
<td>SSc subtype</td>
<td>Limited</td>
<td>$T_{LCO}$ &gt;75%</td>
<td>$T_{LCO}$ &gt;75%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>U3-RNP, Th/To (nucleolar pattern)</td>
<td>U3-RNP, Th/To (nucleolar patterns)</td>
</tr>
<tr>
<td></td>
<td>Autoantibody</td>
<td>$T_{LCO}$ &gt;60%</td>
<td>$T_{LCO}$ &gt;50%</td>
</tr>
<tr>
<td></td>
<td>ACA, U3-RNP, Th/To (nucleolar pattern)</td>
<td>$T_{LCO}$ &gt;50%</td>
<td>$T_{LCO}$ &gt;50%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FVC/TLO &gt;1.6</td>
<td>FVC/TLO &gt;1.6</td>
</tr>
<tr>
<td>PFT results</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td></td>
<td>Normal</td>
<td>$&gt;$30</td>
<td>$&gt;$50</td>
</tr>
<tr>
<td></td>
<td>Right heart catheterisation, $O_2$ desaturation</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td>ECHO, PA systolic pressures (mm Hg)</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td></td>
<td>FVC &gt;75%</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td></td>
<td>$T_{LCO}$ &gt;60%</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td>Other tests</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td></td>
<td>Normal</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td>Patient monitoring</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td></td>
<td>Right heart catheterisation, $O_2$ desaturation</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td></td>
<td>FVC &gt;75%</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td></td>
<td>$T_{LCO}$ &gt;60%</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td></td>
<td>U3-RNP, Th/To (nucleolar pattern)</td>
<td>$&gt;$30</td>
<td>$&gt;$30</td>
</tr>
<tr>
<td>Possible treatments</td>
<td>Tracleer, Remodulin, Floilan, oxygen, coumadin</td>
<td>CTX</td>
<td>Possible CTX, oxygen, coumadin</td>
</tr>
<tr>
<td></td>
<td>CTX</td>
<td>CTX</td>
<td>PFTs, ECHO yearly</td>
</tr>
</tbody>
</table>

**PFTs**, pulmonary fibrosis; **SSc**, systemic sclerosis; **ACA**, anticentromere antibody; **Scl70**, anti-scleroderma 70 antibody; **PFTs**, pulmonary function tests; **ECHO**, echocardiogram; **HRCT**, high resolution CT scan; **BAL**, bronchoalveolar lavage; **CTX**, cyclophosphamide; **TLCO**, carbon monoxide transfer factor; **PA**, pulmonary artery.
pulmonary hypertension. Table 1 lists the various associations and risk factors of the two forms of lung disease that an individual patient is most likely to have. This will guide doctors in evaluating and deciding whether there is an available treatment. However, all patients should have frequent PFTs and echocardiograms to determine the type and incidence of lung disease. With a better understanding of the different types of lung disease and the use of the more specific techniques such as high resolution computed tomography, bronchoalveolar lavage, and right heart catheterisation, we have the best chance of identifying patients with early alveolitis or pulmonary hypertension so that appropriate treatment can be given. Future treatment of these complications is likely to be directed specifically at the fibrosis of the interstitium or the pulmonary vessels or even both. Hopefully, newer drugs will make these lung complications as treatable as angiotensin converting enzyme inhibitors have been for renal crisis.


.....................

Authors’ affiliations
V Steen, Georgetown University, Washington DC, USA

Correspondence to: Professor V Steen; steenv@georgetown.edu

REFERENCES


www.annrheumdis.com
Predictors of end stage lung disease in systemic sclerosis

V Steen

doi: 10.1136/ard.62.2.97

Updated information and services can be found at:
http://ard.bmj.com/content/62/2/97

These include:

References
This article cites 20 articles, 2 of which you can access for free at:
http://ard.bmj.com/content/62/2/97#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Interstitial lung disease (145)
- Immunology (including allergy) (5144)
- Inflammation (1251)
- Pulmonary hypertension (28)
- Connective tissue disease (4253)
- Drugs: musculoskeletal and joint diseases (700)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/